{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T17:00:48Z","timestamp":1780333248070,"version":"3.54.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Fujian Provincial Department of Science and Technology of the People\u2019s Republic of China","award":["No.2023Y4006"],"award-info":[{"award-number":["No.2023Y4006"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"DOI":"10.1186\/s12872-024-04354-4","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T21:01:32Z","timestamp":1743714092000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effect of low-dose aspirin on reducing cardiovascular events and mortality in individuals with CKD stages 3\u20135: a meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"25","author":[{"given":"Jingwen","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqiong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanxian","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maobai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongfu","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"issue":"7","key":"4354_CR1","doi-asserted-by":"crossref","first-page":"e0158765","DOI":"10.1371\/journal.pone.0158765","volume":"11","author":"NR Hill","year":"2016","unstructured":"Hill NR, Fatoba ST, Oke JL, Hirst JA, O\u2019Callaghan CA, Lasserson DS, et al. Global prevalence of chronic kidney disease - A systematic review and Meta-analysis. PLoS ONE. 2016;11(7):e0158765.","journal-title":"PLoS ONE"},{"key":"4354_CR2","doi-asserted-by":"crossref","first-page":"b2392","DOI":"10.1136\/bmj.b2392","volume":"338","author":"T Kurth","year":"2009","unstructured":"Kurth T, de Jong PE, Cook NR, Buring JE, Ridker PM. Kidney function and risk of cardiovascular disease and mortality in women: a prospective cohort study. BMJ. 2009;338:b2392.","journal-title":"BMJ"},{"key":"4354_CR3","doi-asserted-by":"publisher","unstructured":"Vora P, Costa A, Rossignol P, Wanner C, Wilson D, Japp S, et al. Incidence of major cardiovascular outcomes in patients with chronic kidney disease by severity: a United States population-based study using electronic medical records. Eur Heart J. 2023;44(2):ehad655.2746. https:\/\/doi.org\/10.1093\/eurheartj\/ehad655.2746","DOI":"10.1093\/eurheartj\/ehad655.2746"},{"issue":"9731","key":"4354_CR4","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","volume":"375","author":"K Matsushita","year":"2010","unstructured":"Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073\u201381.","journal-title":"Lancet"},{"issue":"10159","key":"4354_CR5","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","volume":"392","author":"regional Global","year":"2018","unstructured":"Global regional. National incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the global burden of Disease Study 2017. Lancet. 2018;392(10159):1789\u2013858.","journal-title":"Lancet"},{"issue":"10","key":"4354_CR6","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.amjcard.2009.01.342","volume":"103","author":"A Dasgupta","year":"2009","unstructured":"Dasgupta A, Steinhubl SR, Bhatt DL, Berger PB, Shao M, Mak KH, et al. Clinical outcomes of patients with Diabetic Nephropathy Randomized to Clopidogrel Plus Aspirin Versus aspirin alone (a post hoc analysis of the Clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] Tria. Am J Cardiol. 2009;103(10):1359\u201363.","journal-title":"Am J Cardiol"},{"issue":"10","key":"4354_CR7","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1161\/ATVBAHA.122.318020","volume":"42","author":"LB Cofer","year":"2022","unstructured":"Cofer LB, Barrett TJ, Berger JS. Aspirin for the primary Prevention of Cardiovascular Disease: time for a platelet-guided Approach. Arterioscler Thromb Vasc Biol. 2022;42(10):1207\u201316.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"11","key":"4354_CR8","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1038\/sj.ki.5001934","volume":"70","author":"D Charytan","year":"2006","unstructured":"Charytan D, Kuntz RE. The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. Kidney Int. 2006;70(11):2021\u201330.","journal-title":"Kidney Int"},{"issue":"9","key":"4354_CR9","first-page":"1285","volume":"38","author":"ZR Yang","year":"2017","unstructured":"Yang ZR, Sun F, Zhan SY. [Risk on bias assessment: (2) revised Cochrane risk of bias tool for individually randomized, parallel group trials (RoB2.0)]. Zhonghua Liu Xing Bing Xue Za Zhi. 2017;38(9):1285\u201391.","journal-title":"Zhonghua Liu Xing Bing Xue Za Zhi"},{"key":"4354_CR10","unstructured":"Deeks JJ, Higgins JPT, Altman DG,Chapter 10: Analysing data and undertaking meta-analyses. In:, Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023. www.training.cochrane.org\/handbook"},{"issue":"3","key":"4354_CR11","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1001\/jama.2018.20578","volume":"321","author":"SL Zheng","year":"2019","unstructured":"Zheng SL, Roddick AJ. Association of Aspirin Use for primary Prevention with Cardiovascular events and bleeding events: a systematic review and Meta-analysis. JAMA. 2019;321(3):277\u201387.","journal-title":"JAMA"},{"issue":"12","key":"4354_CR12","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jacc.2010.02.068","volume":"56","author":"MJ Jardine","year":"2010","unstructured":"Jardine MJ, Ninomiya T, Perkovic V, Cass A, Turnbull F, Gallagher MP, et al. Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. J Am Coll Cardiol. 2010;56(12):956\u201365.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"4354_CR13","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.kint.2020.08.011","volume":"99","author":"R Wolfe","year":"2021","unstructured":"Wolfe R, Wetmore JB, Woods RL, McNeil JJ, Gallagher H, Roderick P, et al. Subgroup analysis of the ASPirin in reducing events in the Elderly randomized clinical trial suggests aspirin did not improve outcomes in older adults with chronic kidney disease. Kidney Int. 2021;99(2):466\u201374.","journal-title":"Kidney Int"},{"issue":"2","key":"4354_CR14","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.kint.2022.09.023","volume":"103","author":"J Mann","year":"2023","unstructured":"Mann J, Joseph P, Gao P, Pais P, Tyrwhitt J, Xavier D, et al. Effects of aspirin on cardiovascular outcomes in patients with chronic kidney disease. Kidney Int. 2023;103(2):403\u201310.","journal-title":"Kidney Int"},{"issue":"2","key":"4354_CR15","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2337\/dc10-1615","volume":"34","author":"Y Saito","year":"2011","unstructured":"Saito Y, Morimoto T, Ogawa H, Nakayama M, Uemura S, Doi N, et al. Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: subanalysis from the JPAD trial. Diabetes Care. 2011;34(2):280\u20135.","journal-title":"Diabetes Care"},{"issue":"3","key":"4354_CR16","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s10557-018-6802-1","volume":"32","author":"M Goicoechea","year":"2018","unstructured":"Goicoechea M, de Vinuesa SG, Quiroga B, Verde E, Bernis C, Morales E, et al. Aspirin for primary Prevention of Cardiovascular Disease and Renal Disease Progression in chronic kidney Disease patients: a Multicenter Randomized Clinical Trial (AASER Study). Cardiovasc Drugs Ther. 2018;32(3):255\u201363.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"2","key":"4354_CR17","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s40256-024-00630-y","volume":"24","author":"I Bellos","year":"2024","unstructured":"Bellos I, Marinaki S, Lagiou P, Benetou V. Aspirin for the Primary Prevention of Cardiovascular Diseases in patients with chronic kidney disease: an updated Meta-analysis. Am J Cardiovasc Drugs. 2024;24(2):241\u201353.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"3","key":"4354_CR18","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1053\/j.ajkd.2004.11.015","volume":"45","author":"C Baigent","year":"2005","unstructured":"Baigent C, Landray M, Leaper C, Altmann P, Armitage J, Baxter A, et al. First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis. 2005;45(3):473\u201384.","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"4354_CR19","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jamainternmed.2021.4813","volume":"181","author":"P Liu","year":"2021","unstructured":"Liu P, Quinn RR, Lam NN, Elliott MJ, Xu Y, James MT, et al. Accounting for age in the definition of chronic kidney disease. JAMA Intern Med. 2021;181(10):1359\u201366.","journal-title":"JAMA Intern Med"},{"issue":"6","key":"4354_CR20","doi-asserted-by":"crossref","first-page":"445","DOI":"10.7326\/0003-4819-156-6-201203200-00007","volume":"156","author":"SC Palmer","year":"2012","unstructured":"Palmer SC, Di Micco L, Razavian M, Craig JC, Perkovic V, Pellegrini F, et al. Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012;156(6):445\u201359.","journal-title":"Ann Intern Med"},{"key":"4354_CR21","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.atherosclerosis.2016.06.013","volume":"251","author":"RW Major","year":"2016","unstructured":"Major RW, Oozeerally I, Dawson S, Riddleston H, Gray LJ, Brunskill NJ. Aspirin and cardiovascular primary prevention in non-endstage chronic kidney disease: a meta-analysis. Atherosclerosis. 2016;251:177\u201382.","journal-title":"Atherosclerosis"},{"issue":"2","key":"4354_CR22","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s11255-019-02350-8","volume":"52","author":"B Qu","year":"2020","unstructured":"Qu B, He Y, Wu L, Lu H, Wu H, Li M. Is there a cardiovascular protective effect of aspirin in chronic kidney disease patients? A systematic review and meta-analysis. Int Urol Nephrol. 2020;52(2):315\u201324.","journal-title":"Int Urol Nephrol"},{"issue":"2","key":"4354_CR23","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/sj.bjc.6601118","volume":"89","author":"TG Clark","year":"2003","unstructured":"Clark TG, Bradburn MJ, Love SB, Altman DG. Survival analysis part I: basic concepts and first analyses. Br J Cancer. 2003;89(2):232\u20138.","journal-title":"Br J Cancer"},{"issue":"1 Suppl 1","key":"4354_CR24","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/S0272-6386(96)90565-X","volume":"28","author":"V D\u2019Agati","year":"1996","unstructured":"D\u2019Agati V. Does aspirin cause acute or chronic renal failure in experimental animals and in humans. Am J Kidney Dis. 1996;28(1 Suppl 1):S24\u20139.","journal-title":"Am J Kidney Dis"},{"key":"4354_CR25","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ijcard.2016.08.224","volume":"223","author":"D Pastori","year":"2016","unstructured":"Pastori D, Pignatelli P, Perticone F, Sciacqua A, Carnevale R, Farcomeni A, et al. Aspirin and renal insufficiency progression in patients with atrial fibrillation and chronic kidney disease. Int J Cardiol. 2016;223:619\u201324.","journal-title":"Int J Cardiol"},{"issue":"6","key":"4354_CR26","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1093\/ndt\/gfn745","volume":"24","author":"M Evans","year":"2009","unstructured":"Evans M, Fored CM, Bellocco R, Fitzmaurice G, Fryzek JP, McLaughlin JK, et al. Acetaminophen, aspirin and progression of advanced chronic kidney disease. Nephrol Dial Transpl. 2009;24(6):1908\u201318.","journal-title":"Nephrol Dial Transpl"},{"issue":"6","key":"4354_CR27","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1053\/j.ajkd.2022.02.019","volume":"80","author":"KR Polkinghorne","year":"2022","unstructured":"Polkinghorne KR, Wetmore JB, Thao L, Wolfe R, Woods RL, Ernst ME, et al. Effect of aspirin on CKD progression in older adults: secondary analysis from the ASPREE Randomized Clinical Trial. Am J Kidney Dis. 2022;80(6):810\u20133.","journal-title":"Am J Kidney Dis"},{"key":"4354_CR28","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1186\/s13063-022-06132-z","volume":"23","author":"H Gallagher","year":"2022","unstructured":"Gallagher H, Dumbleton J, Maishman T, et al. Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiovascular disease in people with chronic kidney disease. Trials. 2022;23:331.","journal-title":"Trials"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-024-04354-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-024-04354-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-024-04354-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T21:02:51Z","timestamp":1743714171000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-024-04354-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,2]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4354"],"URL":"https:\/\/doi.org\/10.1186\/s12872-024-04354-4","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,2]]},"assertion":[{"value":"4 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human Ethics and Consent to participate declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The research reported in this paper adhered to PRISMA guidelines.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Presentations"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"242"}}